Hirsch L J, Mazzone T
J Clin Invest. 1986 Feb;77(2):485-90. doi: 10.1172/JCI112327.
Human monocyte-derived macrophages (HMM) play a key role in the formation of atherosclerotic plaques by accumulating cholesteryl ester (CE) to become foam cells. HMM have receptors for native low density lipoprotein (LDL) and acetylated-LDL (ALDL), and uptake of ALDL can promote substantial cellular CE accumulation. Furthermore, macrophages specifically and saturably bind glucocorticoids, which in turn modulate numerous macrophage functions. Preincubating HMM in dexamethasone-inhibited LDL degradation (230 +/- 12 vs. 515 +/- 21 ng/mg cell protein X 18 h, P less than 0.001) but stimulated ALDL degradation (5.3 +/- 0.5 vs. 2.5 +/- 0.3 micrograms/mg X 18 h, P less than 0.01). These effects were time- and dose-dependent, occurring maximally by 24 h and with 2.5 X 10(-8) M dexamethasone. Dexamethasone increased the maximum velocity for ALDL degradation (16.2 vs. 12.0 micrograms/mg X 18 h, P less than 0.01) without changing the apparent Michaelis constant. Progesterone, 11 alpha-epicortisol, and 17 alpha-OH progesterone (a competitive antagonist of the glucocorticoid receptor) had no effect on HMM ALDL degradation, but 17 alpha-OH progesterone abolished the stimulatory action of dexamethasone. In he presence of ALDL, incorporation of [14C]oleic acid into CE was enhanced over fourfold by dexamethasone (4015 +/- 586 vs. 943 +/- 91 cpm/mg X 2 h, P less than 0.01), and HMM incubated with ALDL and dexamethasone accumulated more free cholesterol (34.6 +/- 1.9 vs. 26.2 +/- 0.8 micrograms/mg, P less than 0.02) and CE (32.8 +/- 2.3 vs. 14.8 +/- 0.8 micrograms/mg, P less than 0.002) than did macrophages without dexamethasone. In cultured human umbilical vein endothelial cells, dexamethasone did not change ALDL degradation, but reduced LDL degradation by 30% (P less than 0.001). In summary, dexamethasone inhibits LDL receptor activity by both macrophages and endothelial cells, but stimulates ALDL receptor activity only in macrophages. These observations provide evidence for the regulation of macrophage endocytic receptors by glucocorticoid hormones.
人单核细胞衍生的巨噬细胞(HMM)通过积累胆固醇酯(CE)形成泡沫细胞,在动脉粥样硬化斑块的形成中起关键作用。HMM具有天然低密度脂蛋白(LDL)和乙酰化LDL(ALDL)的受体,摄取ALDL可促进大量细胞CE积累。此外,巨噬细胞特异性且可饱和地结合糖皮质激素,进而调节多种巨噬细胞功能。用地塞米松预孵育HMM可抑制LDL降解(230±12对515±21 ng/mg细胞蛋白×18小时,P<0.001),但刺激ALDL降解(5.3±0.5对2.5±0.3微克/毫克×18小时,P<0.01)。这些作用具有时间和剂量依赖性,在24小时时最大,地塞米松浓度为2.5×10⁻⁸M。地塞米松增加了ALDL降解的最大速度(16.2对12.0微克/毫克×18小时,P<0.01),而未改变表观米氏常数。孕酮、11α-表皮质醇和17α-羟基孕酮(糖皮质激素受体的竞争性拮抗剂)对HMM的ALDL降解无影响,但17α-羟基孕酮消除了地塞米松的刺激作用。在存在ALDL的情况下,地塞米松使[¹⁴C]油酸掺入CE增加了四倍多(4015±586对943±91 cpm/毫克×2小时,P<0.01),与未用地塞米松处理的巨噬细胞相比,用ALDL和地塞米松孵育的HMM积累了更多的游离胆固醇(34.6±1.9对26.2±0.8微克/毫克,P<0.02)和CE(32.8±2.3对14.8±0.8微克/毫克,P<0.002)。在培养的人脐静脉内皮细胞中,地塞米松不改变ALDL降解,但使LDL降解减少3%(P<0.001)。总之,地塞米松抑制巨噬细胞和内皮细胞的LDL受体活性,但仅刺激巨噬细胞的ALDL受体活性。这些观察结果为糖皮质激素对巨噬细胞内吞受体的调节提供了证据。